Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment

指导刑事司法艾滋病毒预防和治疗方面的新​​调查人员

基本信息

  • 批准号:
    8731476
  • 负责人:
  • 金额:
    $ 18.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-05-15 至 2019-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): David Alain Wohl, MD, an Associate Professor in the Division of Infectious Diseases at the University of North Carolina (UNC), submits this application for a K24 Mid-Career award. The purpose of the K24 is to enable recipients to: a) Devote more time to augment their capabilities in Patient-Oriented Research (POR); and b) Provide mentoring to new clinical investigators in the conduct of POR. Dr. Wohl is a nationally recognized thought-leader in HIV clinical research - particularly that exploring the nexus between incarceration and HIV. In this application he proposes to develop skills that will serve his future work in this significant area of research including qualitative data collection and analysis methodology, higher-level analytical techniques, and strategies for effective leadership. He will expand an established record of mentorship to develop greater capacity and research opportunities in order to foster the research careers of early investigators. Candidate: Dr. Wohl has been a highly productive HIV clinical researcher and has established UNC as a major center for HIV-related corrections research. Since 2003, he has been continuously NIH-funded to conduct research aiming to optimize HIV detection and care for people involved in the criminal justice system, a population with prevalent substance abuse and mental health disorders, and has directly translated the findings of three R01-supported investigations into modification of practice in the NC prison system. Based on his investigations, the NC prison system has adopted antiretroviral self-medication instead of universal directly observed therapy, shifted to voluntary opt-out HIV testing on intake, and developed new transitional care models for HIV-infected releasees. Further, Dr. Wohl has a strong record of teaching and mentorship of new investigators, supporting procurement of awards and first-authored publications by mentees, as well as independence of these talented investigators. Mentoring Plan/Environment: This application will leverage the extensive training resources at UNC including the Center for AIDS Research (CFAR), the School of Public Health-based K30 training program, the School of Medicine MD/PhD program, and the UNC Infectious Diseases research fellowship - each of which Dr. Wohl is deeply involved with. As a founder and Co-Director of the UNC CFAR Prison Working Group, Site Leader of the UNC AIDS Clinical Trials Unit, and Director of the NC AIDS Training and Education Center (ATEC), Dr. Wohl is well-positioned to access and mentor students, fellows and junior faculty within and beyond UNC. As requests for mentoring have increased, Dr. Wohl proposes to receive formal and informal guidance to develop further as a mentor. Further, to better serve those he supervises and enhance his own productively, he seeks this award to strengthen and enhance his data collection and analytical skills including qualitative and quantitative data collection and analysis. Research Plan: The established research infrastructure Dr. Wohl and his collaborators have built, including the establishment of cohorts of HIV-infected and -uninfected prison releasees, and his collaborative relationships with the prison system, public health entities, and other research groups, serve as a platform to provide ample opportunities for mentee research. There remain a number of highly significant questions to be answered across the cascade of HIV care, including: What are the best methods to conduct HIV screening and linkage to care in prison in a manner respects individual autonomy? To what extent are HIV-infected prisoners engaged in care while incarcerated? Can intransigent individual (e.g., substance abuse, mental health disorders, low motivation) and structural (e.g., poverty, discrimination, stigma) obstacles to linkage to HIV care and services after release be surmounted, and if so, how? The K24 support will permit Dr. Wohl the time to pursue work that are natural extensions of his research, and provide rich opportunities for mentee research while protecting time to support his devotion to mentorship.
描述(由申请人提供):北卡罗来纳大学 (UNC) 传染病科副教授 David Alain Wohl 医学博士提交了这份 K24 职业生涯中期奖申请。 K24 的目的是使接收者能够: a) 投入更多时间来增强他们在面向患者的研究 (POR) 方面的能力; b) 为新临床研究者进行 POR 提供指导。沃尔博士是全国公认的艾滋病毒临床研究思想领袖,特别是在探索监禁与艾滋病毒之间的关系方面。在此申请中,他建议培养技能,以服务于他未来在这一重要研究领域的工作,包括定性数据收集和分析方法、更高层次的分析技术以及有效领导的策略。他将扩大已建立的指导记录,以发展更大的能力和研究机会,以促进早期研究人员的研究生涯。候选人:沃尔博士是一位高效的艾滋病毒临床研究员,并将北卡罗来纳大学建立为艾滋病毒相关矫正研究的主要中心。自 2003 年以来,他持续获得 NIH 资助进行研究,旨在优化艾滋病毒检测和对刑事司法系统中涉及的人员、普遍存在药物滥用和精神健康障碍的人群的护理,并直接转化了三个 R01- 的研究结果支持对北卡罗来纳州监狱系统做法修改的调查。根据他的调查,北卡罗来纳州监狱系统采用了抗逆转录病毒自我药疗,而不是普遍的直接观察治疗,转而在入狱时自愿选择退出艾滋病毒检测,并为感染艾滋病毒的释放者开发了新的过渡护理模式。此外,沃尔博士在教学和指导新研究人员、支持受训者获得奖项和第一作者出版物以及这些才华横溢的研究人员的独立性方面拥有良好的记录。指导计划/环境:此应用程序将利用 UNC 的广泛培训资源,包括艾滋病研究中心 (CFAR)、公共卫生学院 K30 培训计划、医学院 MD/PhD 计划和 UNC 传染病中心研究奖学金——沃尔博士深入参与了其中的每一项研究。作为北卡罗来纳大学 CFAR 监狱工作组的创始人和联合主任、北卡罗来纳大学艾滋病临床试验部门的现场负责人以及北卡罗来纳大学艾滋病培训和教育中心 (ATEC) 的主任,沃尔博士有能力接触和指导北卡罗来纳大学内外的学生、研究员和初级教师。随着指导请求的增加,沃尔博士建议接受正式和非正式的指导,以进一步发展成为一名导师。此外,为了更好地为他所监督的人服务并提高自己的生产力,他寻求这个奖项来加强和提高他的数据收集和分析技能,包括定性和定量数据收集和分析。研究计划:沃尔博士及其合作者建立的研究基础设施,包括建立感染艾滋病毒和未感染艾滋病毒的监狱释放者队列,以及他与监狱系统、公共卫生实体和其他研究小组的合作关系,服务于作为一个为学员研究提供充足机会的平台。在艾滋病毒护理的各个环节中,仍有许多非常重要的问题需要回答,包括:以尊重个人自主权的方式进行艾滋病毒筛查和与监狱护理联系的最佳方法是什么?感染艾滋病毒的囚犯在监禁期间接受护理的程度如何?出院后与艾滋病毒护理和服务联系的顽固个人(例如药物滥用、精神健康障碍、积极性低下)和结构性(例如贫困、歧视、耻辱)障碍是否可以克服?如果可以,如何克服? K24 的支持将使沃尔博士有时间从事其研究的自然延伸的工作,并为受指导者的研究提供丰富的机会,同时节省时间来支持他对指导的奉献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A WOHL其他文献

DAVID A WOHL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A WOHL', 18)}}的其他基金

Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment
指导刑事司法艾滋病毒预防和治疗方面的新​​调查人员
  • 批准号:
    9084502
  • 财政年份:
    2014
  • 资助金额:
    $ 18.28万
  • 项目类别:
Mentoring New Investigators in Criminal Justice HIV Prevention and Treatment
指导刑事司法艾滋病毒预防和治疗方面的新​​调查人员
  • 批准号:
    9472311
  • 财政年份:
    2014
  • 资助金额:
    $ 18.28万
  • 项目类别:
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION
HIV 感染中的脂肪重新分布和代谢变化
  • 批准号:
    7716751
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
CLINICAL TRIAL: A5235 - MINOCYCLINE IN THE TREATMENT OF HIV-ASSOCIATED COGNITIVE
临床试验:A5235 - 米诺环素治疗 HIV 相关认知障碍
  • 批准号:
    7716911
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
CLINICAL TRIAL: ENFURVITIDE (T-20) INTENSIFICATION FOR LOW LEVEL VIREMIA (THE LO
临床试验:恩夫维肽 (T-20) 强化治疗低水平病毒血症 (LO
  • 批准号:
    7716849
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
CLINICAL TRIAL: TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE C
临床试验:两剂 GW433908/利托那韦与阿巴卡韦/拉米夫定 C 联用
  • 批准号:
    7716816
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS (SLAM-C)
HCV 和 HIV-1 双重感染受试者的长期抗病毒治疗 (SLAM-C)
  • 批准号:
    7716808
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
CLINICAL TRIAL: MRK AD5 HIV-1 GAG VACCINE IN HIV-1 SUBJECTS WHO INTERUPT THERAPY
临床试验:在中断治疗的 HIV-1 受试者中使用 MRK AD5 HIV-1 GAG 疫苗
  • 批准号:
    7716792
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
CLINICAL TRIAL: PHASE I/II URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY (ACTG A522
临床试验:I/II 期尿苷补充剂治疗 HIV 脂肪萎缩 (ACTG A522
  • 批准号:
    7716871
  • 财政年份:
    2008
  • 资助金额:
    $ 18.28万
  • 项目类别:
Incarceration and HIV-Infected Inmates
监禁和感染艾滋病毒的囚犯
  • 批准号:
    7679078
  • 财政年份:
    2007
  • 资助金额:
    $ 18.28万
  • 项目类别:

相似国自然基金

从CD4+、CD8+T细胞免疫活化分子及其上游调控因子表达探究健脾祛湿法治疗艾滋病免疫调节机制
  • 批准号:
    81460716
  • 批准年份:
    2014
  • 资助金额:
    48.0 万元
  • 项目类别:
    地区科学基金项目
HAART过程中HCV复制增强与肝细胞MAVS抗病毒通路的关系研究
  • 批准号:
    81201286
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Scientific Leadership Group Core
科学领导小组核心
  • 批准号:
    10595900
  • 财政年份:
    2023
  • 资助金额:
    $ 18.28万
  • 项目类别:
RP4 LEAP
RP4飞跃
  • 批准号:
    10595904
  • 财政年份:
    2023
  • 资助金额:
    $ 18.28万
  • 项目类别:
RP5 MPT Study
RP5 MPT 研究
  • 批准号:
    10595905
  • 财政年份:
    2023
  • 资助金额:
    $ 18.28万
  • 项目类别:
IAS 2023, the 12th IAS Conference on HIV Science, Brisbane, Australia, and virtually, 23-26 July 2023
IAS 2023,第 12 届 IAS HIV 科学会议,澳大利亚布里斯班,虚拟会议,2023 年 7 月 23-26 日
  • 批准号:
    10696505
  • 财政年份:
    2023
  • 资助金额:
    $ 18.28万
  • 项目类别:
Hermanos de Luna y Sol: A community-based HIV prevention intervention
Hermanos de Luna y Sol:基于社区的艾滋病毒预防干预措施
  • 批准号:
    10626689
  • 财政年份:
    2023
  • 资助金额:
    $ 18.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了